Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

Derrick Sung Biography and Net Worth

CFO of Pulmonx

Derrick brings to Pulmonx over 20 years of finance, strategy, and commercial experience across multiple facets of the medical device industry. Prior to joining Pulmonx, Derrick was Executive Vice President, Strategy & Corporate Development at iRhythm Technologies, Inc. (NASDAQ: IRTC), where he set strategic and financial direction for the company and helped guide iRhythm through a successful IPO. Prior to iRhythm, Derrick spent seven years on Wall Street as the senior equity research analyst covering the medical device sector for Sanford C. Bernstein & Company. Previously, Derrick was Director of Marketing and Business Development in Boston Scientific Corp.’s Neuromodulation Division; a management consultant at the Boston Consulting Group; and he started his career as an R&D engineer designing heart catheters for Guidant Corporation, now a part of Abbott Vascular. Derrick received his Ph.D. in Bioengineering from the University of California, San Diego; his MBA from San Diego State University, and his B.S. in Mechanical Engineering from Stanford University.

What is Derrick Sung's net worth?: The estimated net worth of Derrick Sung is at least $2.40 million as of September 1st, 2023. Dr. Sung owns 391,041 shares of Pulmonx stock worth more than $2,404,902 as of December 21st. This net worth evaluation does not reflect any other investments that Dr. Sung may own. Learn More about Derrick Sung's net worth.
How do I contact Derrick Sung?: The corporate mailing address for Dr. Sung and other Pulmonx executives is , , . Pulmonx can also be reached via phone at 1-650-364-0400 and via email at [email protected]. Learn More on Derrick Sung's contact information.
Has Derrick Sung been buying or selling shares of Pulmonx?: Derrick Sung has not been actively trading shares of Pulmonx during the last ninety days. Most recently, Derrick Sung sold 4,219 shares of the business's stock in a transaction on Friday, September 1st. The shares were sold at an average price of $10.00, for a transaction totalling $42,190.00. Following the completion of the sale, the chief financial officer now directly owns 391,041 shares of the company's stock, valued at $3,910,410. Learn More on Derrick Sung's trading history.
Who are Pulmonx's active insiders?: Pulmonx's insider roster includes Daniel Florin (Director), Glendon French, III (CEO), David Lehman (General Counsel), Geoffrey Rose (Insider), and Derrick Sung (CFO). Learn More on Pulmonx's active insiders.
Are insiders buying or selling shares of Pulmonx?: In the last twelve months, Pulmonx insiders bought shares 1 times. They purchased a total of 14,245 shares worth more than $97,435.80. In the last twelve months, insiders at the sold shares 23 times. They sold a total of 153,764 shares worth more than $1,392,435.00. The most recent insider tranaction occured on December, 2nd when insider Geoffrey Beran Rose sold 4,376 shares worth more than $27,043.68. Insiders at Pulmonx own 5.7% of the company. Learn More about insider trades at Pulmonx.
Information on this page was last updated on 12/2/2024.

Derrick Sung Insider Trading History at Pulmonx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/1/2023	Sell	4,219	$10.00	$42,190.00	391,041
6/1/2023	Sell	4,222	$11.49	$48,510.78	395,260
3/1/2023	Sell	1,264	$11.03	$13,941.92	261,482
12/14/2021	Sell	3,000	$32.89	$98,670.00
9/20/2021	Sell	3,000	$37.35	$112,050.00
9/1/2021	Sell	383	$40.09	$15,354.47	17,217
4/5/2021	Sell	5,000	$47.60	$238,000.00	223,879

Derrick Sung Buying and Selling Activity at Pulmonx

Pulmonx Company Overview

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Today's Range

Now: $6.15

$5.81

$6.31

50 Day Range

MA: $6.50

$5.93

$7.71

2 Week Range

Now: $6.15

$5.46

$14.84

Volume

329,762 shs

Average Volume

377,457 shs

Market Capitalization

$242.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.69